CM
PACB icon

Castleark Management’s Pacific Biosciences PACB Stock Holding History

Castleark Management’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-141,100
Closed -$4.7M – 353
2021
Q1 		$4.7M Buy
+141,100
New +$4.94M 0.17% 139

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
SM
SB Management Abu Dhabi, United Arab Emirates $516M AUM 40.71% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Castleark Management's PACB Position: Q2 2021 in Review

Castleark Management sold out of Pacific Biosciences (PACB) in Q2 2021, closing a stake of 141,100 shares — an estimated $4.7M sold.

Castleark Management first reported a position in PACB in Q1 2021 and held it in 1 quarter. The position peaked at $4.7M in Q1 2021. 262 funds tracked by Wall St. Rank hold PACB as of Q2 2021.

  • Castleark Management reported no remaining Pacific Biosciences position as of Q2 2021 after selling out during the quarter.
  • Castleark Management sold 141,100 Pacific Biosciences shares in Q2 2021, an estimated $4.7M.
  • Castleark Management first reported a position in Pacific Biosciences in Q1 2021 and held it in 1 quarter.
  • Castleark Management's Pacific Biosciences position peaked at $4.7M in Q1 2021.
  • 262 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2021.

Based on Castleark Management's 13F filing for Q2 2021, filed 17 Aug 2021.